Business
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results
Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics Phase 1 monotherapy data for ERAS-0015 expected in H1 2026 and for ERAS-4001 in H2 2026 Successfully completed $259 million upsized financing in January Robust balance sheet with pro forma cash, cash equivalents, and marketable securities of $434 million expected to fund operations into H2 2028 SAN D
About this update from Erasca, Inc.
[{"type":"image","alt":"Erasca, Inc.","displaySize":"","headline":null,"caption":"Erasca, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":49,"url":"https://media.zenfs.com/en/globenewswire.com/0b48dd84fa0cc496a6fda02f84d9b85c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GvZtDwTaLXBgyqveCpIkiA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY5O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/0b48dd84fa0cc496a6fda02f84d9b85c","width":300,"height":49}},"lazy":false},{"type":"text","content":"Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics","length":198,"tagName":"p"},{"type":"text","content":"Phase 1 monotherapy data for ERAS-0015 expected in H1 2026 and for ERAS-4001 in H2 2026","length":87,"tagName":"p"},{"type":"text","content":"Successfully completed $259 million upsized financing in January","length":64,"tagName":"p"},{"type":"text","content":"Robust balance sheet with pro forma cash, cash equivalents, and marketable securities of $434 million expected to fund operations into H2 2028","length":142,"tagName":"p"},{"type":"text","content":"SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter and full year ended December 31, 2025.","length":371,"tagName":"p"},{"type":"text","content":"“Our RAS-targeting franchise continues to advance rapidly in the clinic, reflecting our strong operational execution and high investigator and patient enthusiasm,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Importantly, the best-in-class potential of our pan-RAS molecular glue ERAS-0015 was underscored by ongoing partial responses at a low dose of 8 mg QD across multiple tumor types and RAS mutations, together with favorable safety and pharmacokinetics (PK) data, as of the data cutoff*. This clinical progress and the successful upsized public offering heighten excitement in our RAS-targeting franchise and strengthen our financial position as we further advance clinical development....